Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is well-positioned for sustainable growth as it continues to scale and expand its market reach, with a strong pipeline of new products and a growing specialized sales force. With a solid financial performance in the first quarter, the company is on track to reach its goal of 100 territories within the next 12 months, and its partnership with SNN provides further opportunities for growth. The company's efficient operational practices and strong EBITDA outlook also bode well for its profitability and long-term success.

Bears say

SI-BONE is highly dependent on external factors such as regulations from governmental and private health-care providers, as well as partnerships with other medical companies like Smith & Nephew. The company's success is also tied to the adoption of their new DRG codes and reimbursement rates for their products, as shown in their projected $50,000 increase in hospital payments per procedure. However, their current valuation at 2x EV/Sales is a premium compared to their ortho & spine peers at 1.8x, and the sector has experienced multiple compression, leading to a decrease in their price target. Additionally, the definition of materiality in the ESG space can change over time, making it difficult to accurately evaluate a company's performance in this area.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.